Bio Techne Corp Stock Pattern Recognition Two Crows

TECH Stock  USD 50.85  -0.62  -1.20%   
The pattern recognition module provides an execution environment for Two Crows recognition and related indicators on Bio Techne. This view tracks pattern recognition signals tied to momentum and continuation to support structured performance interpretation without implying advice.

Recognition
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of forty-nine. The function did not return any valid pattern recognition events for the selected time horizon. Two Crows is a 3-day pattern that warns about a possible future trend reversal for Bio Techne Corp.

Bio Techne Technical Analysis Modules

Most technical analysis of Bio Techne help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Bio from various momentum indicators to cycle indicators. When you analyze Bio charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

Stock Overview, Methodology & Data Sources

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. Bio-Techne operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people. A high-level view of Bio Techne emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/E of 74.38, P/B of 4.01, profit margin of 6.67%. Bio Techne has a market cap of 7.96 B, P/E of 74.38, ROE of 3.97%.

Methodology

Unless otherwise specified, financial data for Bio Techne Corp is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Bio (USA Stocks:TECH) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Bio Techne Corp is covered by 15 analysts. 7 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Stifel, Barclays, Morgan Stanley, Wells Fargo Securities, Evercore ISI, BMO Capital Markets, HSBC Global Research, Jefferies, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board

Become your own money manager

Tracking Bio Techne inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.

Did you try this?

Run Watchlist Optimization Now

   

Watchlist Optimization

Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
All  Next Launch Module

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Corona Opportunity Idea
Corona Opportunity
Invested few shares
Momentum Idea
Momentum
Invested over 20 shares
Macroaxis Index Idea
Macroaxis Index
Invested over 60 shares
Cash Cows Idea
Cash Cows
Invested few shares
Social Domain Idea
Social Domain
Invested few shares
Data Storage Idea
Data Storage
Invested few shares
Video Games Idea
Video Games
Invested few shares
Hedge Favorites Idea
Hedge Favorites
Invested over 200 shares
Artificial Intelligence Idea
Artificial Intelligence
Invested few shares
Investor Favorites Idea
Investor Favorites
Invested few shares

More Resources for Bio Stock Analysis

A structured review of Bio Techne Corp often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Below are reports that help frame Bio Techne Corp Stock in context:
Bio Techne has a market cap of 7.96 B, operating margin of 19.67%, ROE of 3.97%. Use World Market Map to explore allocation context. This includes a position in Bio Techne Corp across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Analysis related to Bio Techne should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
 Quarterly Earnings Growth
0.091
 Dividend Share
0.32
 Earnings Share
0.53
 Revenue Per Share
7.787
 Quarterly Revenue Growth
-0.004
The market value of Bio Techne Corp is measured differently than book value, which reflects Bio accounting equity. Bio Techne's market capitalization is 7.96 B. With a P/B ratio of 4.01, the market values Bio Techne well above its book equity. Enterprise value stands at 8.23 B. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Bio Techne's intrinsic value and market price are different measures derived from different inputs. For Bio Techne, key inputs include a P/E ratio of 74.38, a P/B ratio of 4.01, a profit margin of 6.67%, and ROE of 3.97%. Trading price represents the transaction level agreed by market participants.